logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

Denali Therapeutics Inc.

DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also developsā€¦ read more

Healthcare

Biotechnology

8 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$17.49

Price

-0.46%

-$0.08

$17.57

Previous Close

$17.48

Open

Premium

52w Discount
Market Cap

$2.565b

Mid

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

+34.9%

3y CAGR

+56.9%

5y CAGR
Earnings

-$498.744m

-18.0%

1y CAGR

-51.2%

3y CAGR

-41.5%

5y CAGR
EPS

-$2.91

-13.2%

1y CAGR

-32.1%

3y CAGR

-26.3%

5y CAGR
Book Value

$926.197m

$1.056b

Assets

$129.424m

Liabilities

$44.404m

Debt
Debt to Assets

4.2%

-0.1x

Debt to EBITDA
Free Cash Flow

-$410.847m

-13.0%

1y CAGR

-17.4%

3y CAGR

-17.9%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.